Pharmaceuticals and Medical Research (TRBC) Headlines

  • Cytokinetics sinks on abandoning ALS drug after failed trial

    (Reuters) - Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

    in.reuters.com
  • U.S. FDA approves first two-drug HIV regimen

    NEW YORK (Reuters) - The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at easing the side effects for long-term patients who are on the standard treatment involving three or more drugs.

    in.reuters.com
  • Opioid crisis cost U.S. economy $504 billion in 2015: White House

    WASHINGTON (Reuters) - Opioid drug abuse, which has ravaged parts of the United States in recent years, cost the economy as much as $504 billion in 2015, White House economists said in a report made public on Sunday.

    in.reuters.com
  • Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients: study

    (Reuters) - Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

    in.reuters.com
  • Brexit gets real for drugmakers as regulator moves to Amsterdam

    LONDON (Reuters) - Drugmakers are racing to implement Brexit contingency plans to prepare for a jolt to their regulatory system as the European Medicines Agency is uprooted from London to Amsterdam.

    in.reuters.com
  • Cytokinetics abandons ALS drug after failed trial, shares tank

    (Reuters) - Cytokinetics Inc will stop developing one of its treatments for ALS, which afflicts Stephen Hawking, after the drug failed in a late-stage trial, the company said on Tuesday, sending its shares tumbling about 35 percent.

    in.reuters.com
  • J&J multiple myeloma drug succeeds in first-line combination study

    (Reuters) - Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

    in.reuters.com
  • Roche, AbbVie leukemia drug superior to older medicine in study

    (Reuters) - Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

    in.reuters.com
  • Cytokinetics abandons ALS drug after failed trial

    (Reuters) - Cytokinetics Inc said on Tuesday it would discontinue developing its drug to treat ALS, a fatal neuro-degenerative disorder, after the treatment failed in a late-stage trial.

    in.reuters.com
  • Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs

    MÅLØV, Denmark (Reuters) - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as its established diabetes drugs come under price pressure, particularly in the United States.

    in.reuters.com
  • Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

    LONDON (Reuters) - Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

    in.reuters.com
  • Britain says Canada's Concordia overcharging health service for thyroid drug

    LONDON (Reuters) - Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

    in.reuters.com
  • Substituting methadone for opioids could save billions

    (Reuters Health) - Policymakers and insurers have been pushing people addicted to opioids into abstinence-based detox programs, but a new study concludes that methadone and similar drug-maintenance treatments save lives and money.

    in.reuters.com
  • U.S. judge rejects plea deal with Novelion's Aegerion

    BOSTON (Reuters) - A U.S. judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes into its marketing of a cholesterol drug, saying it was "not in the public interest."

    in.reuters.com
  • Amsterdam, Paris win post-Brexit EU agencies in lucky dip

    BRUSSELS (Reuters) - Amsterdam and Paris won the right to host two EU agencies that must leave London because of Brexit after an extraordinary ministerial meeting in Brussels that left both results decided by drawing lots from a fishbowl.

    in.reuters.com
  • Amsterdam, Paris win post-Brexit EU agencies in lucky dip

    BRUSSELS (Reuters) - Amsterdam and Paris won the right to host two EU agencies that must leave London because of Brexit after an extraordinary ministerial meeting in Brussels that left both results decided by drawing lots from a fishbowl.

    in.reuters.com
  • Amsterdam, Paris win post-Brexit EU agencies in lucky dip

    BRUSSELS (Reuters) - Amsterdam and Paris won the right to host two EU agencies that must leave London because of Brexit after an extraordinary ministerial meeting in Brussels that left both results decided by drawing lots from a fishbowl.

    www.reuters.com
  • Amsterdam, Paris win post-Brexit EU agencies in lucky dip thrillers

    BRUSSELS (Reuters) - Amsterdam and Paris won the right to host the two EU agencies that must leave London on Brexit after a dramatic ministerial meeting in Brussels that left both result decided by drawing lots after votes were tied.

    www.reuters.com